Skip to main content
Immunovant, Inc. logo

Immunovant, Inc. — Investor Relations & Filings

Ticker · IMVT ISIN · US45258J1025 US Professional, scientific and technical activities
Filings indexed 564 across all filing types
Latest filing 2026-03-20 Director's Dealing
Country US United States of America
Listing US IMVT

About Immunovant, Inc.

https://immunovant.com/

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. The company develops monoclonal antibodies designed to treat a range of autoimmune conditions. Its therapeutic approach focuses on targeting the neonatal Fc receptor (FcRn) to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which are central drivers of many autoimmune diseases. The company's pipeline is centered on developing anti-FcRn antibodies, including its product candidate IMVT-1402, for subcutaneous administration.

Recent filings

Filing Released Lang Actions
4 - Immunovant, Inc. (0001764013) (Issuer)
Director's Dealing
2026-03-20 English
4 - IMMUNOVANT, INC. (0001764013) (Filer)
Director's Dealing
2026-02-27 English
10-Q Filing
Interim / Quarterly Report Q3 2026
2026-02-06 English
8-K Filing
Regulatory Filings
2026-02-06 English
4 Filing
Director's Dealing
2026-01-23 English
FORM 4
Director's Dealing
2026-01-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.